Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.5K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Use of antimicrobials in a mother-child university hospital center in Canada: An observational study].

Annales pharmaceutiques francaises·2023
Same author

Understanding and preventing vaccination errors.

Infectious diseases now·2023
Same author

[Clinical pharmacy in four French-speaking university hospitals, integration and supervision of clinical pharmacists: An exploratory study].

Annales pharmaceutiques francaises·2022
Same author

[Surgical antibiotic prophylaxis's usage review in a mother-child university hospital].

Annales pharmaceutiques francaises·2022
Same author

Use of continuous infusion of clonidine for sedation in critically ill infants and children.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

[Exploration of the evolution of antibiotic consumption according to the WHO AWaRe classification, in a mother-child university hospital].

Annales pharmaceutiques francaises·2021

Related Experiment Video

Updated: May 3, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K

[Is pediatrics excluded from pharmaceutical innovation?].

G Hébert1, S Prot-Labarthe2, M-E Tremblay3

  • 1Service de pharmacie, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France; Pharmacie - unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, 3185, chemin de la Côte-Sainte-Catherine, Montréal, Québec H3T 1C5, Canada.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|January 28, 2014
PubMed
Summary

Access to new pediatric drugs is limited in France and Canada, leading to widespread off-label prescribing. This highlights a critical need for more drugs with specific pediatric indications and adapted formulations.

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.5K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Related Experiment Videos

Last Updated: May 3, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.5K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Area of Science:

  • Pediatric pharmacology
  • Drug accessibility and regulation

Background:

  • Therapeutic strategies for children require drugs with approved pediatric indications.
  • Availability of new drugs, especially for pediatric use, varies significantly between countries.
  • This study focuses on the disparity in pediatric drug access between France and Canada.

Purpose of the Study:

  • To compare the market launch and pediatric indications of new drugs in France and Canada during 2009.
  • To identify differences in the availability of new therapeutic drugs for children in these two countries.

Main Methods:

  • A retrospective analysis of newly marketed drugs in France and Canada in 2009.
  • Data collected from official health agencies in France (HAS, Thériaque, ANSM) and Canada (CEPMB, BDPP).

Main Results:

  • France (37) and Canada (30) introduced different numbers of new drugs in 2009.
  • Only 38% of new drugs in France and 27% in Canada had pediatric indications.
  • Most drugs lacked planned pediatric studies, and some with indications lacked age-appropriate formulations.

Conclusions:

  • A significant deficit in new pediatric drugs contributes to extensive off-label prescribing for children.
  • Children often receive medications without approved dosages or suitable pharmaceutical forms.
  • Improvements in pediatric drug development and market authorization are crucial.